HTGC - Hercules Capital, Inc.
The market is very richly priced right now, making high-quality companies trading at a deep discount a rare find. I share two deeply undervalued quality dividend machines yielding up to 11.6% that the market has thrown out with the bathwater. I also share the risks involved and detail why I think they are highly compelling buys right now.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a second quarter 2026 total cash distribution of $0.47 per share. The following shows the key dates of t.
12%-yielding tech lenders Hercules Capital and Trinity Capital now trade at similar 1.3x NAV multiples. I compare them side by side, identifying their pros and cons. I share why I give HTGC the slight edge but also why TRIN might make more sense for some investors.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”). The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually, will mature on July 24, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company's o.
In the latest trading session, Hercules Capital (HTGC) closed at $15.93, marking a -1.24% move from the previous day.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on July 24, 2026. The Notes are unsecured and bear interest at a rate of 6.300% per y.
The latest trading day saw Hercules Capital (HTGC) settling at $16.37, representing a +1.61% change from its previous close.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2026 financial results conference call for Thursday, July 30, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules wi.
Hercules Capital (HTGC) reached $15.69 at the closing of the latest trading day, reflecting a -1.26% change compared to its last close.
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.
In the closing of the recent trading day, Hercules Capital (HTGC) stood at $15.58, denoting a +2.23% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Hercules Capital stands out among BDCs for its resilient, venture-focused portfolio and minimal AI disruption risk. HTGC maintains strong credit quality, with only 0.1% of its portfolio on non-accrual and a 12% yield, supporting a Strong Buy rating. Portfolio composition is 44% healthcare/life sciences and 35% application software, with high barriers to entry and AI beneficiaries.
Hercules Capital is trading at a 30% premium to NAV, down from 72% in 2024, reflecting compressed sentiment around technology-focused BDCs. HTGC is paying out a 12.1% dividend yield, with a $0.40 base and a $0.07 supplemental quarterly dividend. The base dividend was 120% covered by first-quarter net investment income. Portfolio credit quality remains robust, with nonaccruals at fair value at just 0.1% of the total investment portfolio as of the end of the first quarter.
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets.
Hercules Capital (HTGC) closed the most recent trading day at $15.65, moving +1.03% from the previous trading session.
Rent for a studio apartment in many major coastal cities, including Seattle, Boston, New York, Miami, Los Angeles, and San Francisco, commonly falls between $2,100 and $3,200 per month. Using a midpoint of roughly $2,500 per month, that translates to about $30,000 in annual housing costs. The question is simple: how much investment capital is... A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced it has secured $300 million in combined financing. The financing includes a $135 million equity financing alongside up to $165 million in a strategic financing facility with Hercules Capital, Inc. (NYSE: HTGC) across a senior secured debt and royalty structure. Capital will support Beren's growth.
Hercules Capital is a strong buy, trading at a rare 28.4% NAV premium versus its 5-year average of 49.36%. HTGC offers a 12.3% dividend yield, with distributions well covered by net investment income and supported by $149.1M in spillover income. The portfolio is conservatively structured, with 98% floating-rate senior secured loans and non-accruals at just 0.1% of fair value.
Hercules Capital (HTGC) reported earnings 30 days ago. What's next for the stock?